香港联交所最新资料显示，2月2日，摩根大通增持信达生物（01801）123.3667万股，每股作价78.6975 港元，总金额约为9708.65万港元。增持后最新持股数目约为8791.49万股，最新持股比例为5.06%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 香港联交所最新资料显示，2月2日，摩根大通增持信达生物（01801）123.3667万股，每股作价78.6975 港元，总金额约为9708.65万港元。增持后最新持股数目约为8791.49万股，最新持股比例为5.06%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 客户端 ...

商业化稳步推进，2025 年产品收入高增长。2025 年全年产品收入约119 亿元，同比保持约45%的强劲 增长态势；四季度实现产品收入约33 亿人民币，同比增长超60%（因6 款新药首次纳入国家医保目录， 公司按原价格分销至渠道的产品，计提了相应金额的一次性库存补差，对四季度产品收入产生一定影 响）。目前公司肿瘤领域的管线已扩展至13 款，协同效应日益凸显；与此同时，公司成功拓展慢病领 域并实现卓越成果，综合产品线展现强劲增长动力。我们认为，高速增长主要来自于信迪利单抗、奥雷 巴替尼、雷莫西尤单抗等品种持续增长，同时玛仕度肽、托莱西单抗、替妥尤单抗、氟泽雷塞、利厄替 尼等新品快速放量。随着公司6 款产品新进入国家医保目录，我们预计2026 年产品收入将保持高速增 长。 机构：中信建投证券 核心观点 公司2025 全年产品收入约119 亿元，同比保持约45%的强劲增长态势；四季度实现产品收入约33 亿 元，同比增长超60%，再次验证公司优秀的产品竞争力和商业化体系，我们认为高速增长来自原有产品 的持续增长和新产品的快速放量，从治疗领域来看，非肿瘤领域开始贡献重要增量。展望2026 年，公 司将持续发挥核心优势 ...

Core Viewpoint - The company forecasts a product revenue of approximately 11.9 billion yuan for 2025, representing a year-on-year growth of about 45%, with Q4 revenue expected to reach around 3.3 billion yuan, showing over 60% growth year-on-year, aligning with expectations [1] Group 1: Revenue Growth and Product Expansion - The company's product revenue is set to surpass 10 billion yuan for the first time, driven by innovative products [1] - By 2025, the company's oncology product portfolio has expanded to 13 products, with the revenue from the drug Sintilimab expected to be 551 million USD, reflecting a year-on-year growth of approximately 5% [1] - Several potential blockbuster products are anticipated to be approved for market launch in 2025, including Masitinib, Tislelizumab, and Pidilizumab, which are expected to contribute significantly to the company's revenue growth [1] Group 2: New Products and Future Performance - Seven products, including Sintilimab and Tislelizumab, have been added to the national medical insurance directory for 2025, effective from 2026, indicating clear performance drivers for 2026 [2] - The company is expected to focus on the continuous development of innovative molecules like IBI363 and its internationalization process in 2026, with a significant collaboration with Takeda worth 10 billion USD announced in October 2025 [2] - The completion of the collaboration and share transfer with Takeda is anticipated to significantly enhance profits in 2026 [2] Group 3: Profit Forecast and Valuation - The revenue forecast for 2025 has been raised by 5.0% to 12.6 billion yuan, while the net profit forecast for 2026 has been increased by 274% to 6.68 billion yuan, with a new forecast for 2027 net profit set at 4.14 billion yuan [2] - The company maintains an outperform rating, with a target price of 118.3 HKD, indicating a potential upside of 48.06% from the current stock price [2]

香港联交所最新资料显示，2月2日，摩根大通增持信达生物(01801)123.3667万股，每股作价78.6975港 元，总金额约为9708.65万港元。增持后最新持股数目约为8791.49万股，最新持股比例为5.06%。 ...

智通财经APP获悉，香港联交所最新资料显示，2月2日，摩根大通增持信达生物(01801)123.3667万股， 每股作价78.6975港元，总金额约为9708.65万港元。增持后最新持股数目约为8791.49万股，最新持股比 例为5.06%。 ...

| 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 費出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | --- | --- | --- | --- | --- | --- | | | 份數目 | 문 정 | | | 母人口(日)與勢斯和我的(出生的外於) | | | | | | | 合三十十 | | CS20260205E00460 | JPMorgan Chase & Co. | 1001(L) | 1,233,667(L) | HKD 78.6975 | 87,914,889(L) 5.06(L)02/02/2026 | | | | | | | 11.813.057(S) 0.68(S) | | | | | | | 70,953,373(P) 4.09(P) | | 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信達生物製藥 | | 日期(日/月/年): | 06/01/2026 - 06/ | 格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月2日，信达生物(01801.HK)获JPMo ...

来源：新浪基金∞工作室 最新定期报告显示，港股创新药ETF（159567）重仓股包括石药集团、百济神州、康方生物、中国生物 制药、中国生物制药、信达生物、三生制药、翰森制药、科伦博泰生物-B、康哲药业，持仓占比如下。 股票代码股票名称持仓占比持仓股数（股）持仓市值（元）01093石药集团10.44%1.08亿8.25亿06160百 济神州9.91%482.99万7.82亿09926康方生物9.72%752.00万7.68亿01177中国生物制药9.66%1.37亿7.63亿 08027中国生物制药9.66%1.37亿7.63亿01801信达生物9.53%1092.95万7.53亿01530三生制药6.95%2512.55 万5.49亿03692翰森制药6.93%1679.60万5.47亿06990科伦博泰生物-B3.48%77.48万2.74亿00867康哲药业 2.55%1729.70万2.02亿 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.c ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

爱尔眼科发布澄清公告：与恒泰康不存在直接股权或经营管理关系 2月6日，爱尔眼科发布公告称，关注到部分媒体关于精神专科医院涉嫌违规问题的报道中，将襄阳恒泰 康医院有限公司（以下简称"襄阳恒泰康"）与爱尔眼科直接关联。为避免相关传闻对广大投资者及社会 公众造成误导，切实维护投资者合法权益，公司现就有关情况澄清说明如下： 1、襄阳恒泰康非爱尔眼科所属企业。该公司为爱尔医疗投资集团有限公司（以下简称"爱尔医疗投 资"）与其他投资方合资设立的四级子公司。 2、襄阳恒泰康由其医院管理团队经营。爱尔医疗投资不参与襄阳恒泰康的日常经营管理。 （爱尔眼科公告） 礼来：替尔泊肽2025年销量超365亿美元，2026年业绩指引预计达800亿至830亿美元 近日，礼来发布2025年全年财报，公司全年营收651.79亿美元，同比增长45%，其中，礼来明星产品替 尔泊肽在2025年第四季度大卖116.70亿美元，全年总计销售额365.07亿美元。 按 GAAP计算，公司净利润 66.36 亿美元（同比 + 50%），每股收益（EPS）7.39 美元（同比 + 51%），均包含 0.52 美元的收购在研药物（IPR&D）费用。按非 GAA ...

公司的新产品组合维持增长势头，按季增长13%，抵消了Tyvyt的疲弱表现。2025年全年产品销售表现 强劲，同比增长45%至119亿元，首次突破百亿元里程碑，其中普通生物制药业务为主要增长引擎。 信达生物去年第四季产品收入约33亿元人民币(下同)，符合该行预期，在相对较低的基数下同比增长 60%，按季持平，其中包括因应2026年国家医保药品目录降价而产生的渠道返利负面影响。 高盛发布研报称，将信达生物(01801)2025至2027年的每股盈利预测由0.54元、1.43元、2.49元，上调至 0.62元、1.74元及2.54元;目标价102.85港元(原本107.96港元)，予"买入"评级。 ...